Heparin Market Size is projected to reach USD 11.89 Billion by 2030, growing at a CAGR of 6.8%: Straits Research
01 sept. 2022 12h20 HE
|
Straits Research
New York, United States, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Heparin is an anticoagulant and glycosaminoglycan naturally produced by all mammals' basophils and mast cells. It prevents blood clots...
Flowable Hemostats Market Size Worth $458.9 million Globally, by 2028 at CAGR of 7.1% - Exclusive Report by The Insight Partners
13 juil. 2022 08h30 HE
|
The Insight Partners
New York, July 13, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Flowable Hemostats Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Material,...
Worldwide Fractional Flow Reserve Industry to 2027 - Increasing Number of Cath Labs is Driving Growth
07 juil. 2022 05h28 HE
|
Research and Markets
Dublin, July 07, 2022 (GLOBE NEWSWIRE) -- The "Fractional Flow Reserve Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. The fractional...
Autotransfusion Devices Market Size Worth $1.33Bn, Globally, by 2028 at 4.2% CAGR - Exclusive Report by The Insight Partners
07 avr. 2022 11h21 HE
|
The Insight Partners
New York, April 07, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Autotransfusion Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type...
The Worldwide Motorized Thrombectomy Industry is Expected to Reach $1 Billion in 2026
31 janv. 2022 05h38 HE
|
Research and Markets
Dublin, Jan. 31, 2022 (GLOBE NEWSWIRE) -- The "Motorized Thrombectomy Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering. The global motorized...
Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results
12 août 2021 16h05 HE
|
Angion Biomedica Corp.
-- Topline data in ANG-3777 Phase 3 study now expected to be announced in early Q4 rather than at year end -- Phase 1 data demonstrated ANG-3070 was well-tolerated across dose cohorts, achieving drug...
Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury
29 avr. 2021 00h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y. and ST. GALLEN, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN) and Vifor Pharma today announced completion of enrollment for Angion’s AKI-002-15...
Renibus Therapeutics Initiates Phase 2 Study of RBT-1 for Prevention of Acute Kidney Injury
11 mars 2021 09h00 HE
|
Rénibus Therapeutics Inc.
- Renibus plans to enroll 126 subjects at up to 20 sites across the United States, Canada, Australia, and New Zealand DALLAS, Texas, March 11, 2021 (GLOBE NEWSWIRE) -- Renibus Therapeutics®...
ERAS 2021: CHF Solutions to Host On-Demand Presentation on Management of Fluid Overload in Cardiac Surgery Patients
04 mars 2021 08h00 HE
|
CHF Solutions, Inc.
EDEN PRAIRIE, Minn., March 04, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, will...
Renibus Therapeutics Announces Abstract Presentation at the 2020 European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Annual Congress
09 juin 2020 09h00 HE
|
Rénibus Therapeutics Inc.
Dallas, June 09, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc, a clinical-stage biotechnology company, is pleased to announce that data highlighting the translation of the mechanism of action...